Expert Insights

GlobalData Healthcare Expert Insights

Drug approvals and industry crises, Expert Insights are substantiated by quantitative data and market forecasts taken from our own proprietary research

View our Expert Insights, they provide analyst's views on the latest trends and events in the Healthcare industry.

Expert InsightsRSS Feed

  1. Takeda and Ovid to Co-develop Drug for Rare Pediatric Epilepsies

    In this Expert Insight, Christos Michaelides, Ph.D., GlobalData's Analyst covering Neurology and Ophthalmology, discusses Takeda and Ovid Therapeutics' recent announcement that they would be co-developing a drug for rare pediatric epilepsies.

  2. Phase III Failure Puts the Future of Alcobra in Doubt

    In this Expert Insight, Rahael Maladwala, GlobalData's Associate Analyst covering Neurology and Ophthalmology, discusses Alcobra's announcement that its extended release formulation of the drug metadoxine has failed to meet the primary endpoint in its pivotal Phase III trial in which it was administered to children, adolescents, and adults with ADHD.

  3. FDA Hold on Clinical Trials of Vadastuximab Talirine May Be a Temporary Setback to the Drug’s Promising Advance in AML

    In this Expert Insight, Volkan Gunduz, Ph.D., GlobalData's Analyst covering Oncology & Hematology, discusses Seattle Genetics' receipt of a clinical hold or partial clinical hold from the FDA for several early-stage clinical trials of the CD33-directed antibody-drug conjugate vadastuximab talirine in acute myeloid leukemia.

  4. Will Pfizer Take OPKO’s Long-acting Growth Hormone Through to FDA Approval After Disappointing Phase III Results?

    In this Expert Insight, Edit Kovalcsik, Ph.D., GlobalData's Analyst covering Cardiovascular & Metabolic Disorders, discusses the failure of OPKO's Lagova to meet its primary outcome in a Phase III study of growth hormone deficient adults.

  5. Lupus Low Disease Activity State (LLDAS): A Complementary Secondary Endpoint in Clinical Trials

    In this Expert Insight, Sebastian S. Gehrke, Ph.D., Healthcare Analyst for GlobalData, discusses new approaches to treating lupus, which has been plagued with a plethora of late-stage failures over the past decade.

© GlobalData 2017. John Carpenter House, 7 Carmelite Street, London EC4 0BS.